(Reuters) – U.S. drug regulators approved a new customized, cell-based treatment for blood cancer from Johnson & Johnson, the Wall Street Journal reported on Monday.
The Food and Drug Administration cleared Carvykti, a therapy for the treatment of multiple myeloma in adult patients whose disease has worsened despite prior treatments with other drugs, the report added.
(Reporting by Shivani Tanna in Bengaluru; Editing by Subhranshu Sahu)
